Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
6d
GlobalData on MSNUK’s pricing watchdog rejects Alzheimer treatments for the second timeThe UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...
3d
GlobalData on MSNVaccinex plans Nasdaq exit as Alzheimer market pressure growsDespite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
2d
FOX 13 Tampa Bay on MSNIronman athlete diagnosed with Alzheimer’s focuses on new finish line: ‘A time for hope’The Ironman Triathlon is a grueling 140 miles, which includes a 2.4-mile swim, a 112-mile bike ride and a 26.2-mile marathon ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...
Opinion
1dOpinion
Zacks Investment Research on MSNTop Research Reports for Bank of America, Accenture & ServiceNowThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), ...
Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...
Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results